- |||||||||| Torisel (temsirolimus) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors (clinicaltrials.gov) - Sep 5, 2023 P1, N=14, Active, not recruiting, Recruiting --> Active, not recruiting | N=36 --> 14 | Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- |||||||||| Torisel (temsirolimus) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. (Pubmed Central) - Jul 30, 2023 We also provide a user-friendly web portal to help serve the biomedical research community. Our study is a rich resource for investigation of liver cancer biology and pharmacological dependencies and may help enable functional precision medicine.
- |||||||||| Leveraging NLP to Identify Biomarker-Eligible Patients (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2053;
These results were obtained from NLP analysis of attending physician notes and did not require manual searching for copies of actual genomic reports. This approach can potentially expedite identification of non-small cell lung cancer patients for complex clinical trials.
- |||||||||| Torisel (temsirolimus) / Pfizer, afuresertib (LAE002) / Laekna Therap
Journal, IO biomarker, Machine learning: Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning. (Pubmed Central) - Jul 10, 2023 Finally, high-risk groups were more sensitive to MR-1220, GSK2110183 and temsirolimus, indicating that risk characteristics could predict drug sensitivity in TNBC patients to a certain extent. This study proposes an immunophenotype-based risk assessment model that provides a more accurate prognostic assessment tool for patients with TNBC and also predicts new potential compounds by performing machine learning algorithms.
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - Jul 5, 2023 P3, N=397, Active, not recruiting, This study proposes an immunophenotype-based risk assessment model that provides a more accurate prognostic assessment tool for patients with TNBC and also predicts new potential compounds by performing machine learning algorithms. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Clinical, Adverse events, Combination therapy, Metastases: In patients with advanced solid tumors who have been heavily pretreated, combination therapy with #bevacizumab, #temsirolimus, and valproic acid was feasible, but numerous adverse events were observed, which will require careful management. @BlessieNelson https://t.co/NiH6O3osfT (Twitter) - Jun 28, 2023
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion, Phase classification, Enrollment change, Metastases: FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 26, 2023 P1, N=10, Completed, Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=16 --> 10
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jun 15, 2023 P1, N=155, Active, not recruiting, Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=16 --> 10 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
P1 data, Journal, Combination therapy, Metastases: A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. (Pubmed Central) - Jun 13, 2023 P1 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Combination therapy with bevacizumab, temsirolimus, and valproic acid was feasible, but there were numerous toxicities, which will require careful management for future clinical development (ClinicalTrials.gov Identifier: NCT01552434).
- |||||||||| sirolimus / Generic mfg.
Review, Journal: Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer. (Pubmed Central) - May 27, 2023 Current evidence suggests that tumors with mutations in the mTOR signal transduction pathway are sensitive to rapalogue treatment; the rapalogues are metabolized by cytochromes such as CYP3A4, CYP3A5, and CYP2C8 and transported by ABC transporters that are known to vary in activity in individuals; and that tumors can express these transporters and detoxifying enzymes. This results in three levels of genetic analysis that could impact the effectiveness of the mTOR inhibitors.
- |||||||||| perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial completion: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (clinicaltrials.gov) - May 25, 2023 P1, N=10, Completed, Targeting the autophagy-associated proteins and pathways may hint towards a new prospective in the treatment of critically ill patients with SI-AKI, but more preclinical studies are still warranted to validate this hypothesis. Active, not recruiting --> Completed
- |||||||||| lomibuvir (VX 222) / Trek Therapeutics, Metopirone (metyrapone) / HRA Pharma, Torisel (temsirolimus) / Pfizer
Preclinical, Journal: Drug repurposing approach against chikungunya virus: an in vitro and in silico study. (Pubmed Central) - May 18, 2023 Furthermore, in silico molecular docking studies performed by targeting CHIKV structural and non-structural proteins revealed that these drugs can bind to structural protein targets such as envelope protein, and capsid, and non-structural proteins NSP2, NSP3 and NSP4 (RdRp). Findings from in vitro and in silico studies reveal that these drugs can suppress the infection and replication of CHIKV and further in vivo studies followed by clinical trials are warranted.
- |||||||||| Torisel (temsirolimus) / Pfizer
Enrollment open: Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG (clinicaltrials.gov) - May 17, 2023 P1, N=12, Recruiting, Findings from in vitro and in silico studies reveal that these drugs can suppress the infection and replication of CHIKV and further in vivo studies followed by clinical trials are warranted. Not yet recruiting --> Recruiting
- |||||||||| Mekinist (trametinib) / Novartis, Torisel (temsirolimus) / Pfizer
Journal: Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma. (Pubmed Central) - May 16, 2023 Strikingly, the efficacy of temsirolimus was amplified by combining the treatment with the Mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Our findings provide a scientific rationale for the simultaneous inhibition of mTOR and MEK as a novel strategy for the treatment of MM.
- |||||||||| Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma, Torisel (temsirolimus) / Pfizer
METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA (Illusion) - May 12, 2023 - Abstract #EHA2023EHA_2319; We propose a promising treatment combining an asparagine and glutamine degrader(Erwinase) with a PI3KS inhibitor (Torisel) that should be considered as a therapeutic option in a bridge-to- transplant approach for R/R T-ALL/LL with PI3KS deregulation. We show that metabolic plasticity conveys a unique and targetable vulnerability in PI3KS-driven leukemia that show promising results in pre-clinical and clinical settings.
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Torisel (temsirolimus) / Pfizer
Journal: The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches. (Pubmed Central) - May 11, 2023 Since mTOR resistance mechanisms prevent the effects of mTOR inhibitors used in cancer treatments, new inhibition strategies should be developed. Inhibition approaches are created using nanoparticles, and one of them offers a promising treatment option with evidence supporting its effectiveness.
- |||||||||| Inlyta (axitinib) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: ADONIS: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (clinicaltrials.gov) - May 1, 2023 P=N/A, N=573, Completed, Alternating sunitinib and temsirolimus did not improve the PFS in patients with mRCC. Trial completion date: Apr 2021 --> Sep 2022 | Trial primary completion date: Apr 2021 --> Sep 2022
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Temsirolimus in Combination With Metformin in Patients With Advanced Cancers (clinicaltrials.gov) - Apr 7, 2023 P1, N=87, Active, not recruiting, Additionally, AFP response may be a more sensitive predictor of disease response than RECIST in HB. Trial completion date: Oct 2022 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2024
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (clinicaltrials.gov) - Apr 7, 2023 P1, N=278, Active, not recruiting, Trial completion date: Oct 2022 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2024 Trial completion date: Dec 2022 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Apr 2024
- |||||||||| RAPA-201 / Rapa Therap
Phase classification, Trial completion date, Trial primary completion date: RAPA-201 Therapy of Solid Tumors (clinicaltrials.gov) - Mar 30, 2023 P1/2, N=22, Recruiting, These findings may inform novel treatment strategies for PM. Phase classification: P2 --> P1/2 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- |||||||||| Torisel (temsirolimus) / Pfizer
COMBINATORY ANTI-TUMOR ACTIVITIES OF BANOXANTRONE AND TEMSIROLIMUS AGAINST COLORECTAL CANCER (ePoster - DDW Online Platform) - Mar 23, 2023 - Abstract #DDW2023DDW_355; Our findings suggest that arctigenin performs well to add to current treatment in ccRCC and confirm the value to target EGFR to improve therapy in RCC. Based on the cooperative anti-tumor activity of AQ4N/AQ4 and temsirolimus, the combination of banoxantrone plus temsirolimus has potential as a treatment option for CRC in clinical settings.
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene, ganitumab (AMG 479) / Takeda, ImmunityBio, Torisel (temsirolimus) / Pfizer
Enrollment open, Metastases: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov) - Mar 15, 2023 P1, N=20, Recruiting, Based on the cooperative anti-tumor activity of AQ4N/AQ4 and temsirolimus, the combination of banoxantrone plus temsirolimus has potential as a treatment option for CRC in clinical settings. Not yet recruiting --> Recruiting
- |||||||||| Torisel (temsirolimus) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Transcriptome-driven combination design: A computational approach (Section 32; Poster Board #9) - Mar 14, 2023 - Abstract #AACR2023AACR_5726; Dasatinib, temsirolimus, and cabozantinib were newly predicted effective after treatment with each and every kinase inhibitor. This data suggests an avenue for the design of intelligent drug combinations based on anticipated transcriptomic changes that may improve on existing synergy prediction methods.
- |||||||||| Torisel (temsirolimus) / Pfizer
Liver regeneration after radiation therapy: clinical observations and a new rat model (Section 3; Poster Board #17) - Mar 14, 2023 - Abstract #AACR2023AACR_5396; Our results suggest that protecting the normal liver outside the irradiated area enhances the probability of successful regeneration to compensate for radiation-induced liver injury. PI3K/AKT/mTOR is essential in liver regeneration after irradiation, and carbamazepine may enhance liver regeneration after irradiation in rats.
|